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Poststroke dementia commonly occurs following stroke, with its pathogenesis related to β-amyloid production and apoptosis.
The present study evaluate the eﬀects of paeonol, one of the phenolic phytochemicals isolated from the Chinese herb Paeonia
suﬀruticosa Andrews (MC), on protection from memory loss after ischemic stroke in the subacute stage. Rats were subjected to
transient middle cerebral artery occlusion (tMCAo) with 10min of ischemia. The data revealed that paeonol recovered the step-
through latency in the retrieval test seven days after tMCAo, but did not improve the neurological deﬁcit induced by tMCAo.
Levels of Amyloid precursor protein (APP)- and beta-site APP cleaving enzyme (BACE; β-secretase)-immunoreactive cells, and
terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL)-positive cells decreased in the paeonol-
administered group. Western blotting revealed decreased levels of Bax protein in mitochondria and apoptosis-inducing factor
(AIF) in cytosol following paeonol treatment. In conclusion, we speculate that paeonol protected memory after ischemic stroke
via reducing APP, BACE, and apoptosis. Supression the level of Bax and blocking the release of AIF into cytosol might participate
in the anti-apoptosis provided by paeonol.
1.Introduction
Cognitive impairment is a commonly occurring sequela
following stroke and is the second leading cause of dementia
intheelderly,afterAlzheimer’sdisease[1,2].Themajorityof
stroke survivors suﬀer from various cognitive dysfunctions,
including dementia (which exists in 25% of stroke patients),
linked with disability, poor functional outcome, and life
dissatisfaction [3]. With recent improvements in the medical
treatment of stroke, survival rates have increased, and the
prevention and treatment of vascular cognitive impairment
and vascular dementia after stroke have become increasingly
important [3].
Although there are diﬀerences in the causes of the
diseases, poststroke dementia shares common mechanisms
with Alzheimer’s disease, including the augmentation of β-
amyloid production and tau protein phosphorylation [4,
5]. Following ischemic episode, the expression of amyloid
precursor protein (APP) upregulates β-amyloid oligomers in
the brain’s extracellular spaces [6–8], and amyloid precursor
protein production increases in astrocytes [9]. Then, the
interactions between β-amyloid and several factors, includ-
ing apolipoproteins, presenilins, tau protein, α-synuclein,
inﬂammation factors, and neuronal survival/death decisions
in the brain, contribute to ischemic brain degeneration,
leading to white matter damage and neuronal cell death
[5, 7]. Excepting necrotic cell death which happens within
minutes, neuronal death (including apoptosis) commences
severalhoursafterischemicstrokeandlastsseveraldays[10].
Therapies which can salvage neuronal cells from apoptosis
in ischemic penumbra might improve patient outcomes after
ischemic stroke [11].
Paeonol (2 -hydroxy-4 -methoxyacetophenone)isoneof
the phenolic phytochemicals isolated from the Chinese herb2 Evidence-Based Complementary and Alternative Medicine
Paeonia suﬀruticosa Andrews (MC), and widely consumed as
a nutrient supplement in a Chinese medical formula which
had the third highest sales volumes in Beijing during 2007
and 2009 [12]. In an animal study, paeonol attenuated neu-
rotoxicity and ameliorated cognitive impairment induced
by d-galactose [13]. The present group has previously
demonstrated that paeonol reduced the infarct area in a
transient middle cerebral artery occlusion (tMCAo) rat
model [14]. It also attenuated oxidative stress-induced APP
expression in a cell model [15].
To investigate the validity of paeonol in protection
of memory after stroke, rat model of tMCAo was used.
Neurological status and memory was tested seven days
after tMCAo. Levels of APP, beta-site APP cleaving enzyme
(BACE), and apoptosis in brain tissue were evaluated. Then,
the levels of proteins that participate in apoptotic intrinsic
andextrinsicpathwayswerealsomeasured.Thedatarevealed
that paeonol protected memory after ischemic stroke via
reducing APP, BACE, and apoptosis. Suppression of level of
mitochondrial Bax and cytosolic AIF might also participate
in the protective eﬀect.
2.MaterialsandMethods
2.1. Animals and Chemicals. All experimental procedures
were performed on adult male Sprague-Dawley rats, weigh-
ing 300 to 350g, according to the guidelines approved by the
Care and Use of Laboratory Animals Committee of China
Medical University. Adequate measures were taken to min-
imize animals’ pain or discomfort. Rats were housed under
light-dark—(12h/12h) and room temperature—controlled
conditions.
Paeonol was isolated and puriﬁed from the root bark
of Paeonia suﬀruticosa as described previously [14]. Freshly
prepared paeonol was ﬁrst dissolved in tetraglycol and then
diluted in phosphate-buﬀered saline (PBS; 137mM NaCl,
1.4mM KH2PO4,4 . 3m MN a 2HPO4, 2.7mM KCl, pH 7.2)
to reach a ﬁnal concentration of 2mg/mL in a 5% solution
of tetraglycol in PBS. Chloral hydrate (Merck, Darmstadt,
Germany) was dissolved in water to a stock concentration of
400mg/mL.
2.2. Occlusion Model. Ischemia was induced via intraluminal
suture occlusion of the middle cerebral artery (MCA) as
describedpreviously[16].Brieﬂy,ratswereanesthetizedwith
chloral hydrate (400mg/kg, i.p.). The right common carotid
artery (CCA) and internal carotid artery (ICA) were exposed
via a midline incision in the neck. The pterygopalatine artery
was ligated close to its origin. A 3/0 nylon ﬁlament suture,
blunted at the tip by a ﬂame and coated with poly-L-lysine
(Sigma, USA), was advanced from the right external carotid
artery through the CCA and up to the ICA for a distance of
20 to 25mm to block the origin of the MCA. After 10min of
ischemia,thenylonsuturewasremovedtoallowreperfusion.
2.3. Grouping and Experiment. A total of 36 rats were
randomly divided into three groups: paeonol group, vehicle
group, and sham group. Rats in the paeonol group were
pre-administered paeonol one hour before introduction of
tMCAo. A dose of 20mg/kg (i.p.) was chosen according to
our previous study, which revealed that 20mg/kg of paeonol
exhibits the best neuroprotective eﬀect [14]. After 10min
of ischemia, rats were subjected to reperfusion. Rats in the
vehicle group were subjected to the same procedure as rats
in the paeonol group, but PBS was administered instead
of paeonol. Rats in the sham group underwent the same
procedure as rats in the vehicle group, but the origin of the
MCA was not occluded.
One day before tMCAo, rats underwent habituation and
training for the passive avoidance trial. One hour before
tMCAo, rats underwent the retention trial. Twenty-four
hours after tMCAo, the neurological status were measured.
The second retention trial and evaluation of neurological
status were performed on the seventh day after tMCAo.
Rats were then sacriﬁced for Western blotting and termi-
naldeoxynucleotidyltransferase-mediateddUTP-biotinnick
end labeling (TUNEL) and immunohistochemical (IHC)
staining.
2.4. Measurement of Neurological Status. The neurological
status of each rat was measured using Modiﬁed Neurological
Severity Score, 24 hours after reperfusion, by an investigator
blind to the treatment group. Motor, sensory, balance, and
reﬂex functions were assessed based on a neurological deﬁcit
score (18-point scale) described by Chen et al. [17]. Brieﬂy,
motor tests included placing the rat on the ﬂoor (inability
to walk straight was scored as 1, circling toward paretic side
was scored as 2, and falling down to the paretic side was
scoredas3)andraisingeachratbyitstail(ﬂexionofforelimb
was scored as 1, ﬂexion of hindlimb was scored as 1, and
head moving >10◦ was scored as 1). Sensory tests included
tactile (deﬁciency, 1) and pushing paw against table edge
(deﬁciency, 1) subtests. Ability to balance on the beam was
scored as follows: rats grasped onto side of a beam, 1; hugged
the beam and one limb slipped oﬀ the beam, 2; hugged the
beam and two limbs slipped oﬀ the beam, 3; attempted to
balancebutfelloﬀ(>40s),4;attemptedtobalancebutfelloﬀ
(<20s), 5; fell oﬀ the beam without any attempt to balance,
6. Reﬂex tests included pinna reﬂex (deﬁciency, 1), corneal
reﬂex (deﬁciency, 1), and startle reﬂex subtests (deﬁciency,
1). Abnormal movement was scored (seizure, 1).
2.5. Passive Avoidance Test. The passive avoidance apparatus
consisted of two chambers of the same size (25 × 20 ×
17cm high) connected via a guillotine door (9 × 7cm).
The ﬂoor of each chamber was made of 14 stainless steel
rods (6mm in diameter), spaced 1.8cm center to center, and
wired to a shock scrambler (Gemini Avoidance System, San
Diego Instruments, San Diego, CA, USA). For habituation
the rats were placed in the right chamber of the apparatus
and, 5sec later, the house light was turned on and the
guillotine door was raised. Upon entering the dark chamber,
the guillotine door was closed and 30sec later the rats
were taken out from the dark chamber and put into their
home cages. Entrance latency into the dark compartment
was recorded when the animal had placed all four paws
into the dark chamber. If the animal waited for more than
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the experiment. The habituation was repeated 30min later
and followed after the same interval by a training session.
During the training session the guillotine door was closed
and an intermittent electric shock (50Hz, 3s, 0.5mA) was
delivered to the ﬂoor of the dark chamber immediately after
the animals had enter the dark chamber. After 30sec, the rat
was taken from the dark chamber and placed into its home
cage. Then after 2min, the training session was repeated.
The rat received a footshock each time it reentered the dark.
Training was terminated when the rat remained in the light
compartment for 120sec. The numbers of trials (entering
the dark chamber) were recorded. The retention trial was
performed 24 hours and seven days after tMCAo. After
the house light was on and the guillotine door was open,
the step-through latency (STL) into the dark chamber was
recorded for up to 300sec. If the rat did not enter the dark
chamber after 300sec, the retention trial was terminated and
a ceiling score of 300sec was assigned.
2.6. IHC Assay. For ICH and TUNEL staining, rats were
transcardially perfused with 200mL of 0.9% saline and
200mL of 4% paraformaldehyde (PFA, pH 7.4). Rat brains
were removed quickly and postﬁxed in 4% PFA followed
by 30% sucrose (wt/vol) for three days and then cut
into 15μm sections using a cryostat. Brain sections were
rinsed with Dulbecco’s phosphate-buﬀered saline (DPBS,
Sigma, USA) containing 0.01% Tween-20 and immersed
in 3% H2O2/methanol for 15min to inhibit endogenous
peroxidase activity. Thereafter, sections were incubated with
10% normal animal serum (Zymed, CA, USA) for 20min
at room temperature. The sections were incubated in moist
chambers with primary anti-APP (1:100 dilution, mouse
monoclonal, 22C11, Chemicon, Billerica, MA, USA) and
anti-BACE (1:100 dilution, Chemicon) for one hour at
37◦C. Following incubation with secondary antibody and
avidine-biotin peroxidase complex (ABC kit, Zymed, CA,
USA) sections were colored using a 3,3 -diaminobenzidine
(DAB) kit (Scytek Laboratories, Logan, U.T, USA), and
then counterstained with hematoxylin. The stained sections
were mounted in mounting media (Assistant-Histokitt,
Germany) and immunoreactive cells were counted under the
microscope (Axioskop 40, Zeiss). Immunoreactive cells were
counted for nine consecutive high power ﬁelds (HPFs) along
the CA1 region and nine HPF within a square in the MCA
territory of the cortex (Figure 3(a)). Negative control stains
were performed on adjacent sections in the control group
andsubjectedtothesameIHCassayprocedures,butwithout
primary antibodies.
2.7. TUNEL Assay. TUNEL staining was performed accord-
ing to the manufacturer’s instructions of a commercial
kit (Merck KGaA, Darmstadt, Germany) to identify cells
with nuclear DNA fragmentation. Brieﬂy, the brain sec-
tions, which were chosen adjacent to those used for IHC
were incubated with proteinase K (20μg/mL) for 20min
and then incubated with 1X TdT equilibration buﬀer for
30min at room temperature, followed by incubation with
TdT labeling reaction mixture for 1.5h at 37◦C. After
addition of stop solution and blocking buﬀer, sections
were incubated with conjugate solution for 30min at room
temperature and TUNEL positive cells were visualized using
DAB kit. Finally, sections were counterstained with methyl
green.
2.8. Western Blotting Analysis. For Western blotting, rats
were anesthetized using choral hydrate and perfused tran-
scardially with 400mL of 0.9% saline. Brains were removed,
coronally sectioned from −4.3 to +1.7mm bregma, and
separatedintotherightcortex,rightstriatum,leftcortex,and
left striatum. The right cortex was weighed and the cytosolic
and mitochondrial proteins were separated using a commer-
cial kit (BioVision, Mountain View, CA, USA). Protein con-
centrationsofthecytosolicandmitochondrialfractionswere
determined usingBio-Radassay.The proteinextracts(10μg)
were then separated using 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, transferred to nitrocel-
lulose membranes, probed with antibodies, and detected
using peroxidase-conjugated anti-rabbit antibody followed
by chemiluminescence as described previously [18]. The
antibodyagainstactin(dilution1:5000)waspurchasedfrom
Chemicon. Antibodies against cytochrome c (1:1000 dilu-
tion), Bax (1:1000 dilution), B-cell leukemia/lymphoma-
2 (Bcl-2) (1:1000 dilution), and tumor necrosis factor
receptor type 1-associated death domain (TRADD) (1:1000
dilution) were purchased from Cell Signaling (Beverly,
MA, USA). Antibodies against apoptosis-inducing factor
(AIF) (1:100 dilution) and Fas-associated death domain
(FADD)(1:1000dilution)werepurchasedfromCalbiochem
(San Diego, CA, USA), antibody against cleaved caspase-8
(1:1000 dilution) was purchased from BioVision (Moun-
tain View, CA, USA), and that against Cox4 (1:5000)
was purchased from Abcam (Cambridge, MA, USA). The
intensities of bands on the gel were calculated using
Gel-Pro Analyzer (Media Cybernetics Inc., Bethesda, MD,
USA).
2.9. Statistical Analysis. Data are expressed as mean ± SD.
Data of sham, vehicle, and paeonol groups were compared
using one-way ANOVA followed by posthoc Scheﬀe’s test. A
probability value of less than 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Eﬀects of Paeonol on Neurological Deﬁcit Induced by
tMCAo. There were three groups of rats: sham, vehicle, and
paeonol. Rats in the vehicle and paeonol groups received
tMCAo via a 10min occlusion of the MCA, while rats in the
sham group received a sham operation. Rats in the paeonol
group were pre-administered paeonol one hour before
tMCAo. Twenty-four hours after tMCAo, rats in the vehicle
and paeonol groups presented neurological deﬁcit scores of
7.0±0.8 (range, 6–8) and 5.5±2.5 (range, 5–8), respectively.
Seven days after tMACo the neurological deﬁcit score was
5.4 ± 2.0 in the vehicle group and 4.3 ± 2.7 in the paeonol
group. There were no signiﬁcant diﬀerences in neurological
deﬁcit score between vehicle and paeonol groups either 24
h o u r so rs e v e nd a y sa f t e rt M C A o( Figure 1).4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Eﬀects of paeonol on neurological defect 24 hours and
seven days after tMCAo. Seven days after tMCAo, rats presented
with a total neurological deﬁcit score of 18 points. 13–18 represents
severe injury; 7–12 represents moderate injury; 1–6 represents mild
injury.
∗∗∗P < 0.001 compared to sham group (n = 12).
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Figure 2: Eﬀects of paeonol on step-through latency (STL) in
retention trial seven days after tMCAo. Paeonol (20mg/kg) was
administered 1h before tMCAo.
∗∗P < 0.05 compared to sham
group; ##P < 0.05 compared to vehicle group (n = 12).
3.2. Eﬀects of Paeonol on STL in the Passive Avoidance Test.
In the passive avoidance test, rats were shocked in order to
train them to avoid going into the dark chamber 24 hours
before tMCAo. Performance of retention trials immediately
before tMCAo ensured the rats had remembered the shock
from 24 hours previously. Then, repeat of the retention trials
seven days after tMCAo tested if the rats had remembered
the shock one week previously. Data revealed that the STL
intothedarkchamberwassigniﬁcantlyshorterinthecontrol
group than in the sham group seven days after tMCAo.
Paeonol pretreatment signiﬁcantly reversed the decrease in
STL induced by tMCAo (P = 0.007) (Figure 2).
3.3. Paeonol Reduced the Expression of APP and BACE in
the Ischemic Brain Seven Days after tMCAo. IHC staining
evaluated APP- and BACE-expressing cells within the dotted
line areas of the brain coronal section (Figure 3(a)). On
day seven after tMCAo, the sham group presented minimal
APP and BACE immunoreactivity. The CA1 area of hip-
pocampus and MCA territory of the cortex in the vehicle
group demonstrated increased APP immunoreactivity. Rats
in the paeonol group demonstrated smaller increases in
APP immunoreactivity in the CA1 and cortical areas than
those in the vehicle group (Figures 3(b), 3(c), 3(d), and
3(e)). tMCAo induced increases in the numbers of BACE-
immunoreactive cells in the MCA territory of the cortical
region. However, the paeonol group demonstrated reduced
BACE immunoreactivity (Figures 4(a) and 4(b)). The CA1
area contained no BACE immunoreactive cells in the sham,
vehicle, and paeonol groups. These data suggest that paeonol
suppressed tMCAo-induced APP in the CA1 and cortex and
also suppressed BACE expression in the cortex.
3.4. Eﬀects of Paeonol on Apoptosis Seven Days after tMCAo.
TUNEL staining detected apoptotic cells seven days after
tMCAo. There were no TUNEL-positive cells in the cortical
area in the sham group (Figures 5(a) and 5(b)). The number
of TUNEL-positive cells in the MCA territory of the cortical
region in the vehicle group substantially increased seven days
after tMCAo. In contrast, the paeonol group demonstrated
marked reductions in TUNEL-positive cells compared to
the vehicle group. Cell counts showed that paeonol reduced
the number of TUNEL-positive cells to 52.3% (Figure 5(b)).
There were no TUNEL-positive cells in the CA1 region in
sham, vehicle, or paeonol groups.
To determine the possible pathways in which paeonol
might participate to suppress apoptosis, the present study
extracted cytosolic and mitochondrial proteins from the
ischemic cortex for Western blot analysis. Of the apoptosis-
related proteins examined, tMCAo increased AIF by more
than twofold in both cytosolic and mitochondrial fractions.
Paeonol suppressed this increase in AIF in the cytosol. In
mitochondria, levels of AIF protein in the paeonol group
did not diﬀer from those in the vehicle group. tMCAo
induced 3.74-fold increases in mitochondrial Bax protein
while paeonol treatment reduced the induced Bax to 1.62-
fold of its baseline value. Administration of paeonol did
not alter cytosolic Bcl-2, Bax, cytochrome c, caspase-8,
FADD, and TRADD protein levels and also did not modify
mitochondrial Bcl-2 and cytochrome c (Figure 6).
4. Discussion
Based on previous studies which identiﬁed that paeonol
improves cognitive functions and inhibits APP expression
[13, 15], the present study examined paeonol’s potential
memory protective eﬀects in a cerebral ischemic rat model.
Data demonstrated that paeonol protected memory in a sub-
acute stage seven days after tMCAo. The possible molecularEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: APP immunohistochemistry in the hippocampus and ischemic cortex seven days after tMCAo. (a) The region within the
rectangular dotted line indicates the CA1 sector, and the region within the square dotted line indicates the MCA territory of cortex, for
calculation of APP-immunopositive cells. (b) Representative photographs showing APP immunoreactivity in the hippocampal CA1 area. (c)
APP-positive cells per 400X microscopic ﬁeld in the CA1 area. (d) Representative photographs showing APP immunoreactivity in the cortex.
(e) APP-positive cells per 400x microscopic ﬁeld in the cortex. In (b,d), scale bar represents 100μm. Arrows indicate APP-immunoreactive
cells. In (c,e),
∗P<0.05,
∗∗P<0.01, and
∗∗∗P<0.001, refer to the diﬀerences from the vehicle group. Error bars denote S.E.M (n = 6).
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Figure 4: BACE immunohistochemistry in the ischemic cortex seven days after tMCAo. (a) Representative photographs showing BACE
immunoreactivity in the cortex. Scale bar represents 100μm. Arrows indicate BACE-immunoreactive cells. (b) BACE-positive cells per 400x
microscopic ﬁeld in the cortex. Error bars denote SEM. In (b),
∗∗∗P<0.001, refers to the diﬀerences from the vehicle group (n = 6).Evidence-Based Complementary and Alternative Medicine 7
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Figure 5: Eﬀects of paeonol on apoptosis in the ischemic cortex seven days after tMCAo. (a) Representative photographs showing TUNEL
staining in the ischemic cortex. Scale bar represents 100μm. Arrows indicate TUNEL-positive cells. (b) TUNEL-positive cells per 400x
microscopic ﬁeld in the cortex. Error bars denote S.E.M.
∗∗P<0.01 and
∗∗∗P<0.001, refer to the diﬀerences from the vehicle group
(n = 6).
mechanisms included the reduction of β-amyloid levels and
the suppression of apoptosis. Procedures also identiﬁed Bax
and AIF as the key molecules suppressed by paeonol during
the apoptotic process.
Prior research has identiﬁed that paeonol exerts neuro-
protective eﬀects and reduces the infarct area in cerebral
artery occlusion and cerebral ischemia-reperfusion models
[17, 19, 20]. The protection of paeonol against neuronal
damage is previously ascribed to its antioxidative activities.
In one study, paeonol increased superoxide dismutase and
glutathione activities [13]. In another study, paeonol attenu-
ated hydrogen peroxide-induced transcription factor NF-κB
[15], which is highly relevant in the inﬂammatory process
following ischemic stroke [21]. Zhong et al. also attributed
the improvements to cognitive impairment induced by d-
galactose, which generates superoxide anion and oxygen-
derived free radicals, to the antioxidative ability provided by
paeonol [13].
In this study, paeonol had no signiﬁcant eﬀects on
neurological deﬁcit on the ﬁrst or seventh day after reper-
fusion, conﬂicting with our previous study that showed
paeonol reduced the neurological deﬁcit scores. The incon-
sistency might come from the diﬀerent neurological deﬁcits
generated by diﬀerent ischemic time periods in the two
studies. In that previous study, the rats underwent tMCAo
that blocked MCA for 90 minutes before reperfusion,
generating a severe injury with the neurological deﬁcit score
m o r et h a n1 3[ 14, 20]; however, rats hardly survived more
than 48 hours. In this study, in order to examine memory
in the subacute stage of ischemic stroke, we abandoned the
severe deﬁcit model and adopted moderate deﬁcit model
that blocked the blood ﬂow for 10 minutes, generating the
neurological deﬁcit score of 7.0 ± 0.8 (range, 6–8). We
proposed that it was because that the neurological deﬁcit
scores were smaller in this study than that in our previous
one, the data could not show a statistical signiﬁcance, even
the mean neurological deﬁcit score was lower in paeonol
group.Althoughpaeonoldidnotsigniﬁcantlyprotectneuro-
logicalfunctionsinthismodel,paeonolreversedthetMCAo-
induced decreases in STL in a passive avoidance retrieval
test, indicating that paeonol protected memory after cerebral
ischemia.
In previous studies, paeonol improved learning ability
and enhanced memory in a D-gal-injured brain, tested using
the Morris water maze and passive avoidance tests [13].
Paeonol also altered behaviors of learning in rats following8 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Western blot analysis of apoptosis-related proteins from cytosolic and mitochondrial fractions. Data are shown as mean ± SEM of
ﬁve independent assays. The percentage below each lane represents the amount of protein relative to the sham group.
∗P<0.05 compared
with the vehicle group.
β-amyloid injection [22]. Amyloidopathy is one of the
main mechanisms of pathogenesis in poststroke dementia.
A number of prior investigations observed upregulation
of APP and β-amyloid following cerebral ischemia, mainly
in astrocytes of the hippocampal CA1 area [23–25], and
also in the cortex and corpus callosum one to four weeks
after ischemia-reperfusion, leading to dense plaque-like
formationafteraninemonthfollowup[4].Thepresentstudy
observed increased APP in hippocampal and cortical areas
seven days after tMCAo, and attenuation of APP increases in
both regions following paeonol treatment. However, the role
of APP in the central nervous system remains controversial.
One of the APP products is the deleterious β-amyloid,
while another APP product, sAPPα, may participate in
neuroprotection, synaptic plasticity, neurite outgrowth, and
synaptogenesis [26]. Increased APP expression might also
participate in the protection against endoplasmic reticulum
stress [27]. Base on our data, we speculated that APP wasEvidence-Based Complementary and Alternative Medicine 9
not the key factor for neuronal damage seven days after
tMCAo, because there was no apoptosis and no infarction
observed in hippocampus (data not shown), even APP level
was up-regulated in the same area. On the other hand,
the coinduction and colocalization of BACE with apoptosis
after tMCAo in cortex suggested that BACE played a more
deleterious role than APP.
ThethreetypesofproteaseswhichcleaveAPPtogenerate
β-amyloid are α-, β-, and γ-secretase [28]. Among the three
secretases, BACE coexpresses most highly with β-amyloid
[29,30],andcontrolstherate-limitingstepintheproduction
of β-amyloid [31]. The high correlation between BACE
and β-amyloid renders BACE being considered one of the
eﬀective therapeutic targets to treat β-amyloid-related dis-
eases [32, 33]. In previous studies, focal ischemia increased
the activity of BACE, especially BACE1, in the ischemic
cortex [7] and thalamus [34]. Consistent with a previous
s t u d yb yW e ne ta l .[ 7], the present study observed BACE
induction and apoptosis occurred in the same location, that
is, ischemic cortex, suggesting the high relevance of BACE
and apoptosis in ischemic stroke. Paeonol treatment limited
the induction of BACE and suppressed apoptosis, indicating
that suppression of β-amyloid production by paeonol might
closely link to the suppression of apoptosis, and might
participate in the memory protection after cerebral ischemia.
After cerebral ischemia, apoptosis occurs in CA1 within
three days of cerebral ischemia, disappears after seven days,
and do not reoccur after a further seven days [35, 36]. In
the present study, apoptosis was observed in the ischemic
cortex, but not in the CA1 region, seven days after tMCAo.
Thesuppressionofapoptosisintheischemiccortexindicated
that paeonol protected neuronal cells from tMCAo injury.
In recent research, paeonol also has been shown to inhibit
glutamate-induced apoptosis in PC12 cells [37] and in rat
brains receiving β-amyloid injection [22], while the detailed
mechanisms relating to the suppression of apoptosis in
neuronal cells have yet to be identiﬁed. There are two
general pathways of apoptosis following cerebral ischemia:
the intrinsic and extrinsic pathways. The intrinsic pathway is
initiated by the accumulation of intracellular Ca2+ following
the depletion of energy after ischemia [10]. Activation of
calpains by Ca2+ results in cleaving of the Bcl-2 interacting
domain(BID)toitstruncatedform(tBID),whichtargetsthe
outer mitochondrial membrane and induces conformational
changes in proapoptotic proteins, such as Bak, Bax, Bad, and
Bcl-XS. These pro-apoptotic proteins can also heterdimerise
with antiapoptotic proteins, including Bcl-2 or Bcl-XL
[38]. The binding of tBID to pro-apoptotic proteins opens
the mitochondrial transition pore, leading to the release
of cytochrome c and AIF into the cytosol [39]. Once
released from mitochondria, cytochrome c binds to and
activates caspase-9, and then caspase-3, which cleaves poly
(ADP-ribose) polymerase (PARP), leading to DNA injury
and caspase-dependent apoptotic cell death [40]. Cytosolic
AIF further translocates into the nucleus and stimulates
caspase-independentDNAfragmentation[41].Theextrinsic
pathway starts from the activation of the cell surface Fas and
tumor necrosis receptors. The Fas receptor triggers FADD
directly and tumor necrosis receptor triggers FADD via
TRADD, activating caspase-8, and then caspase-3, resulting
in PARP cleavage and DNA damage [42]. The present study
is the ﬁrst to identify Bax and AIF as the two main molecules
modiﬁed by paeonol which paeonol can adjust during the
suppression of apoptosis following cerebral ischemia.
The reduction of Bax by paeonol suggests that paeonol
might suppress the apoptosis by inhibiting the release
of mitochondrial factor into cytosol. The simultaneous
suppression of cytosolic AIF supported this assumption.
However,levelofcytochromecwasnotsigniﬁcantlychanged
by paeonol, although the mean value of cytochrome c was
lower in the paeonol group (0.89-fold sham) than that in
the vehicle group (1.29-fold sham). We proposed that the
small enhancement of cytochrome c decreased the statistical
signiﬁcance. A report by Zhu et al. described that after
cerebral ischemia, AIF expression was more pronounced
in neurons of the male brain, while female brain neurons
showed marked increases in expression of caspase-3 [43].
The present study with male rats induced a 2.47-fold of
elevated AIF in cytosol, which was reversed to almost
baseline levels. There are only a few herbs which are known
to regulate the expression of AIF. Isatis indigotica [44]
and polyphyllin D [45] increase the release of AIF from
mitochondria, causing apoptosis, while berberine inhibits
AIF and therefore suppresses apoptosis [46].
Medicinal plant extracts and natural antioxidants might
have potential use in the prevention and treatment of
dementia[2,47].Resultsfromthepresentstudyindicatethat
paeonol, which derives from a widely administered medici-
nal herb, protects the memory following cerebral ischemia.
Paeonol treatment reduced APP and BACE expression, and
also the numbers of apoptotic cells. Suppression of the level
of Bax protein and blocking AIF from releasing to the cytosol
might also be the mechanisms in which paeonol exerted its
eﬀect on anti-apoptosis and memory protection.
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